ASCO® 2022

Presentations

SGN-PDL1V | Solid Tumors | Abstract #TPS3154

Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress)